Evaluation of a Home-based NMES Therapy for Knee Osteoarthritis Pain (NMES)

A Randomized, Sham Controlled, Double-blind, Multi-center Study of Neuromuscular Electrical Stimulation (NMES) as an Adjunctive Therapy for Knee Pain Relief and Improving Functional Outcomes in Knee Osteoarthritis (OA) Patients

Evaluation of knee pain and functional mobility of knee osteoarthritis patients with a home-based neuromuscular electrical stimulation (NMES) therapy

Study Overview

• Status: Completed
• Conditions: Knee Osteoarthritis
• Intervention / Treatment: Device: CyMedica e-vive NMES

• Study Type: Interventional
• Enrollment (Actual): 159
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Tucson, Arizona, United States, 85704
      • Noble Clinical Research
    • Tucson, Arizona, United States, 85712
      • Site 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 85 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject must provide written, informed consent before any study procedures occur. The subject should be provided with a copy of the signed Informed Consent upon signature.

2. Subjects with symptomatic Kellgren-Lawrence (KL) Grade 2, 3, or 4 OA by radiograph (AP tunnel view) within 30 days prior to day 0 visit, where the K-L grades are defined as:

   • Grade 0: no radiographic features of OA are present
   • Grade 1: doubtful joint space narrowing (JSN) and possible osteophytic lipping
   • Grade 2: definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph
   • Grade 3: multiple osteophytes, definite JSN, sclerosis, possible bony deformity
   • Grade 4: large osteophytes, marked JSN, severe sclerosis and definite bony deformity
3. Subject must have a normal tibiofemoral angle (0-8°) and a joint space width of ≥ 3mm confirmed by radiograph.
4. Subjects who are between the ages of 21 - 85 years.
5. Subjects must have a visual analog pain (VAS) score of at least 4 cm on a 10 cm scale for a nominated activity in the target knee at the time of screening.
6. For bilateral knee osteoarthritis subjects, the visual analog pain VAS score for a nominated activity of the contralateral knee must be less than 4 cm on the VAS scale.
7. Subject has access to a smartphone or tablet (Android or iOS).
8. Subject must be ambulatory.
9. Subject must be willing to discontinue receiving knee intra-articular injections of steroids, knee intra-articular injections of hyaluronic acid, opioids, and analgesics (except for acetaminophen up to 3000 mg/day or an equivalent) for the duration of the study.
10. Subject must be willing to take acetaminophen (up to 3000 mg/day) or an equivalent as pain medication for the duration of the study.
11. Subject must be willing to stop taking any pain medications 24 hours prior any scheduled study visit.
12. Subject must be willing to stop receiving knee physical therapy of the target knee for the duration of the study.
13. Subject must be willing to stop wearing any knee unloader brace of the target knee for the duration of the study.
14. Subjects must be proficient in English.
15. Subjects must be willing and able to comply with all study procedures for the duration of the clinical study

Exclusion Criteria:

1. Subjects who have a body mass index ≥ 40 at the time of consent (at the discretion of the PI).
2. Subjects with a diagnosis of inflammatory arthritis (knee rheumatoid arthritis, active gout, knee joint infection, Lyme disease, SLE, etc.).
3. Subjects with a diagnosis of severe neuropathy condition for the past 6 months and under medication for treatment of the condition.
4. Subjects with a diagnosis of fibromyalgia for the past year.
5. Subjects who have had an injury or an acute traumatic injury to the target knee within 6 months of screening.
6. Subject must NOT have had arthroscopy of the target knee within 8 weeks of randomization.
7. Subjects who have had treatment of the target knee with intra-articular injections of steroids within 8 weeks of screening.
8. Subjects who have had intra-articular injections of hyaluronic acid within 12 weeks of screening.

9. Subjects who have had a scheduled surgery on the target knee within the study period.

   (Note- Subjects who are scheduled to go under total knee replacement surgery within the next 3 months at screening will not be enrolled. Subjects that are contemplating the surgery can be included.)

10. Subjects who have used electrotherapy or acupuncture for OA of the target knee within 4 weeks of screening.
11. Subjects who have used Neuromuscular Electrical Stimulation (NMES) in the past year.
12. Subjects with significant and clinically evident mal-alignment of the target knee (> 5 degrees varus or valgus in the target knee).
13. Subjects with surgical metallic hardware in the target knee.
14. Subjects who have had implanted electrical devices (cardiac pacemakers, deep brain stimulators, implantable cardiac defibrillators).
15. Subjects who have contraindications to X-rays.
16. Subjects with a current malignancy or who have received treatment for malignancy with the last 5 years, with the exception of resected basal cell carcinoma and squamous cell carcinoma of the skin.
17. Subjects who have an active substance abuse problem (drugs or alcohol) or a history of chronic substance abuse (> 5 years).
18. Subjects with skin breakdown or infection in the area where the study device will be placed (quadriceps of the target knee).
19. Subjects with any chronic conditions (e.g., diabetes, hypertension, congestive heart failure, etc.) that have not been well-controlled for at least 3 months prior to screening.
20. Subjects who have any ongoing litigation for worker's compensation.
21. Subjects with any condition, in the opinion of the Investigator that might interfere with the evaluation of the study objectives.
22. Subjects who are pregnant.
23. Subject must not have participated in a clinical study within the past 12 weeks from the last day of treatment that required the use of an investigational device, drug or biologic

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Active NMES	Device: CyMedica e-vive NMES; Neuromuscular Electrical Stimulation (NMES) therapy
SHAM_COMPARATOR: Modified NMES sham	Device: CyMedica e-vive NMES; Neuromuscular Electrical Stimulation (NMES) therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Knee pain using VAS scale (Visual Analog Scale)	Pain associated with knee osteoarthritis- Unit none (score)	12 weeks post intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Timed Up & Go (TUG)	Mobility and functionality assessment of the knee- Timed Up & Go (TUG), unit seconds	12 weeks post intervention
Quadriceps muscle strength	Strength assessment, Quadriceps strength using a handheld dynamometer, unit lbs/in	12 weeks post intervention
Repeated Chair Rise	Mobility and functionality assessment of the knee- Repeated chair rise, unit none (number of times)	12 weeks post intervention
3 min walk test	Mobility and functionality assessment of the knee- 3 min walk test, unit meters	12 weeks post intervention
KOOS JR. Survey	Mobility and functionality assessment of the knee- KOOR JR- Unit, none (score)	12 weeks post intervention
WOMAC Survey	Mobility and functionality assessment of the knee- WOMAC- Unit, none (score)	12 weeks post intervention

Collaborators and Investigators

• Sponsor: CyMedica Orthopedics, Inc

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 8, 2019
• Primary Completion (ACTUAL): July 30, 2020
• Study Completion (ACTUAL): November 24, 2020

Study Registration Dates

• First Submitted: October 7, 2019
• First Submitted That Met QC Criteria: October 14, 2019
• First Posted (ACTUAL): October 16, 2019

Study Record Updates

• Last Update Posted (ACTUAL): November 25, 2020
• Last Update Submitted That Met QC Criteria: November 24, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: knee pain; arthritis; knee OA
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: CM-2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No